Human medicines European public assessment report (EPAR): Winlevi, clascoterone, Date of authorisation: 17/10/2025, Status: Authorised

Annex to 16-19 June 2025 CHMP Minutes

Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 26, Status: Authorised

Minutes of the CHMP meeting 16-19 June 2025

Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 16, Status: Authorised

Article 57 product data

List of eligible industry stakeholder organisations

Members of the Coordinating group of European network of paediatric research at the European Medicines Agency (Enpr-EMA)

Ledipasvir/sofosbuvir product-specific bioequivalence guidance

Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting, European Medicines Agency, Amsterdam, the Netherlands, from 3 February 2026 to 4 February 2026